Identification

Name
Hydralazine
Accession Number
DB01275
Type
Small Molecule
Groups
Approved
Description

A direct-acting vasodilator that is used as an antihypertensive agent.

Structure
Thumb
Synonyms
  • (1Z)-1(2H)-Phthalazinone hydrazone
  • (2H)-Phthalazinone hydrazone
  • 1-Hydrazinophthalazine
  • 1-Phthalazinylhydrazine
  • 6-Hydralazine
  • Hidralazina
  • Hydralazin
  • Hydralazinum
  • Hydrallazine
  • Hydrazinophthalazine
  • Hydrazone 1(2H)-phthalazinone
  • Hypophthalin
  • Idralazina
  • Phthalazin-1-ylhydrazine
Product Ingredients
IngredientUNIICASInChI Key
Hydralazine hydrochlorideFD171B778Y304-20-1ZUXNZUWOTSUBMN-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ApresolineSolution20 mgIntravenousSterimax Inc1992-12-31Not applicableCanada
Apresoline Tablets, 10mgTablet10 mgOralSterimax Inc1952-12-312005-07-22Canada
Apresoline Tablets, 25mgTablet25 mgOralSterimax Inc1952-12-312005-07-19Canada
Apresoline Tablets, 50mgTablet50 mgOralSterimax Inc1952-12-312005-07-19Canada
Hydralazine Hydrochloride InjectionSolution20 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Hydralazine-10 Tab 10mgTablet10 mgOralPro Doc Limitee1991-12-312010-07-13Canada
Hydralazine-25 TabTablet25 mgOralPro Doc Limitee1994-12-312010-07-13Canada
Hydralazine-50 TabTablet50 mgOralPro Doc Limitee1994-12-312010-07-13Canada
Jamp-hydralazineTablet25 mgOralJamp Pharma Corporation2017-08-28Not applicableCanada
Jamp-hydralazineTablet50 mgOralJamp Pharma Corporation2017-08-28Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydralazineTablet10 mgOralApotex Corporation1990-12-31Not applicableCanada
Apo-hydralazineTablet25 mgOralApotex Corporation1991-12-31Not applicableCanada
Apo-hydralazineTablet50 mgOralApotex Corporation1991-12-31Not applicableCanada
HydralazineTablet25 mg/1OralCardinal Health2009-09-14Not applicableUs
HydralazineTablet50 mg/1OralNivagen Pharmaceuticals, Inc.2017-02-15Not applicableUs
HydralazineTablet100 mg/1OralNivagen Pharmaceuticals, Inc.2017-02-15Not applicableUs
HydralazineTablet50 mg/1OralCardinal Health2009-09-14Not applicableUs
HydralazineTablet25 mg/1OralNivagen Pharmaceuticals, Inc.2017-02-15Not applicableUs
Hydralazine HydrochlorideTablet50 mg/1OralMylan Institutional2007-12-26Not applicableUs
Hydralazine HydrochlorideTablet25 mg/1OralPar Pharmaceutical1980-02-272020-04-30Us49884 0027 01 nlmimage10 fb20fdf7
International/Other Brands
Alphapress (Alphapharm) / Aprezin (Johnson) / Cesoline W (Pharmasant) / Cesoline Y (Pharmasant) / Diazide (The Central) / Hidral (Biocontrol) / Pressfall (Nisshin Seiyaku) / Serpathiazide (Washington)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BiDilHydralazine hydrochloride (37.5 mg/1) + Isosorbide Dinitrate (20 mg/1)Tablet, film coatedOralRemedy Repack2013-10-082016-04-05Us
BiDilHydralazine hydrochloride (37.5 mg/1) + Isosorbide Dinitrate (20 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2005-06-23Not applicableUs12948 0001 12 nlmimage10 2f131798
BiDilHydralazine hydrochloride (37.5 mg/1) + Isosorbide Dinitrate (20 mg/1)Tablet, film coatedOralArbor Pharmaceuticals2012-12-05Not applicableUs
Ser-AP-ES TabHydralazine hydrochloride (25 mg) + Hydrochlorothiazide (15 mg) + Reserpine (0.1 mg)TabletOralNovartis1960-12-312000-08-02Canada
Categories
UNII
26NAK24LS8
CAS number
86-54-4
Weight
Average: 160.1759
Monoisotopic: 160.074896276
Chemical Formula
C8H8N4
InChI Key
RPTUSVTUFVMDQK-UHFFFAOYSA-N
InChI
InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)
IUPAC Name
1-hydrazinylphthalazine
SMILES
NNC1=NN=CC2=CC=CC=C12

Pharmacology

Indication

For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

Structured Indications
Pharmacodynamics

A vasodilator, hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. It is commonly used in the condition of pregnancy called preeclampsia.

Mechanism of action

Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. It has also been suggested that cyclic 3',5'-adenosine monophosphate (cyclic AMP) mediates, at least partly, the relaxation of arterial smooth muscle by altering cellular calcium metabolism, which interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state. In hypertensive patients, the hydralazine-induced decrease in blood pressure is accompanied by increased heart rate, cardiac output, and stroke volume, probably because of a reflex response to decreased peripheral resistance. The drug has no direct effect on the heart. Hydralazine may increase pulmonary arterial pressure, as well as coronary, splanchnic, cerebral, and renal blood flow. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output. Hydralazine usually increases renin activity in plasma, presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption. Tolerance to the antihypertensive effect of the drug develops during prolonged therapy, especially if a diuretic is not administered concurrently. In patients with CHF, hydralazine decreases systemic vascular resistance and increases cardiac output.

TargetActionsOrganism
AMembrane primary amine oxidase
inhibitor
Human
UProlyl 4-hydroxylase subunit alpha-1
inhibitor
Human
Absorption

Hydralazine is rapidly and extensively absorbed (up to 90%) from the gastrointestinal tract and undergoes extensive first-pass metabolism by genetic polymorphic acetylation. Oral bioavailability of hydralazine is dependent upon acetylator phenotype. Bioavailability is approximately 31% in slow acetylators and 10% in fast acetylators.

Volume of distribution
Not Available
Protein binding

87%

Metabolism

Hydralazine, when administered orally, undergoes extensive first-pass metabolism by genetic polymorphic acetylation, which is responsible for a threefold range of oral bioavailability. Intravenously administered hydralazine does not undergo first-pass metabolism and, therefore, is not affected by acetylator phenotype. After the drug reaches the systemic circulation, it is combined with endogenous aldehydes and ketones, including pyruvic acid, to form hydrazone metabolites. The active metabolites, hydralazine acetonide hydrazone and hydralazine pyruvate hydrazone, are equipotent with the parent, hydralazine.

Route of elimination

Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.

Half life

3 to 7 hours

Clearance
Not Available
Toxicity

Oral LD50 in rats: 173 and 187 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Arylamine N-acetyltransferase 1NAT1*14ANot AvailableG > A | T > A | C > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*14BNot AvailableG > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*15Not AvailableC > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*17Not AvailableC > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*19ANot AvailableC > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*19BNot AvailableC > T | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 1NAT1*22Not AvailableA > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5ANot AvailableT > C | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5BNot AvailableT > C | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5CNot AvailableT > C | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5DNot AvailableT > CADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5ENot AvailableT > C | G > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5FNot AvailableT > C | C > T | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5GNot AvailableT > C | C > T | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5HNot AvailableT > C | C > T | A > G | S287 FrameshiftADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5INot AvailableT > C | C > T | A > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*5JNot AvailableT > C | C > T | G > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*6ANot AvailableG > A | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*6BNot AvailableG > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*6CNot AvailableG > A | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*6DNot AvailableG > A | C > T | T > CADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*6ENot AvailableG > A | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*7ANot AvailableG > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*7BNot AvailableG > A | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*10Not AvailableG > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*12DNot AvailableG > A | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14ANot AvailableG > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14BNot AvailableG > A | C > TADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14CNot AvailableG > A | T > C | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14DNot AvailableG > A | C > T | G > AADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14ENot AvailableG > A | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14FNot AvailableG > A | T > C | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*14GNot AvailableG > A | C > T | A > GADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*17Not AvailableA > CADR InferredAssociated with systemic lupus erythematosus.Details
Arylamine N-acetyltransferase 2NAT2*19Not AvailableC > TADR InferredAssociated with systemic lupus erythematosus.Details

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hydralazine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydralazine.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Hydralazine.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Hydralazine.Approved
AlclofenacAlclofenac may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydralazine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Hydralazine is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Hydralazine.Experimental
AlprenololHydralazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanHydralazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineHydralazine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Hydralazine.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydralazine.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Hydralazine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Hydralazine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Hydralazine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Hydralazine.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Hydralazine.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Hydralazine.Approved
ApocyninApocynin may decrease the antihypertensive activities of Hydralazine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Hydralazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Hydralazine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Hydralazine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydralazine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Hydralazine.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydralazine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Hydralazine.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Hydralazine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Hydralazine.Experimental
BarbitalBarbital may increase the hypotensive activities of Hydralazine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Hydralazine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Hydralazine.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Hydralazine.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Hydralazine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hydralazine.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Hydralazine.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Hydralazine.Withdrawn
BepridilHydralazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydralazine.Approved
BethanidineBethanidine may increase the hypotensive activities of Hydralazine.Approved
BevoniumBevonium may decrease the antihypertensive activities of Hydralazine.Experimental
BietaserpineHydralazine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostHydralazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Hydralazine.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Hydralazine.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Hydralazine.Approved, Investigational
BQ-123Hydralazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Hydralazine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hydralazine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Hydralazine.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Hydralazine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydralazine.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Hydralazine.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Hydralazine.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Hydralazine.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydralazine.Approved, Investigational
BupranololHydralazine may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Hydralazine.Approved
CadralazineHydralazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineHydralazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Hydralazine.Approved
CandoxatrilHydralazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Hydralazine.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Hydralazine.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Hydralazine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hydralazine.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Hydralazine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Hydralazine.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Hydralazine.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
CeliprololHydralazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Hydralazine.Withdrawn
ChloroquineChloroquine may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydralazine.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hydralazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydralazine.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Hydralazine.Approved
CicletanineHydralazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Hydralazine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydralazine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Hydralazine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Hydralazine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Hydralazine.Approved
ClonixinClonixin may decrease the antihypertensive activities of Hydralazine.Approved
CloranololHydralazine may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hydralazine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Hydralazine.Approved, Investigational
CryptenamineHydralazine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Hydralazine.Investigational
CyclopenthiazideHydralazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideHydralazine may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Hydralazine.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Hydralazine.Investigational
DebrisoquinHydralazine may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilHydralazine may increase the hypotensive activities of Delapril.Experimental
DeserpidineHydralazine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydralazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydralazine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Hydralazine.Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Hydralazine.Approved
diethylnorspermineHydralazine may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Hydralazine.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Hydralazine.Approved
DihydralazineHydralazine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydralazine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Hydralazine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Hydralazine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydralazine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Hydralazine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydralazine.Approved
DorzolamideHydralazine may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Hydralazine.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Hydralazine.Approved
DuloxetineHydralazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Hydralazine.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Hydralazine.Investigational
EfonidipineHydralazine may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydralazine.Approved, Vet Approved
EnalaprilatHydralazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineHydralazine may increase the hypotensive activities of Endralazine.Experimental
EpanololHydralazine may increase the hypotensive activities of Epanolol.Experimental
EpirizoleEpirizole may decrease the antihypertensive activities of Hydralazine.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Hydralazine.Approved
EpoprostenolHydralazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Hydralazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Hydralazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Hydralazine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Hydralazine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydralazine.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Hydralazine.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Hydralazine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Hydralazine.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Hydralazine.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Hydralazine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Hydralazine.Approved
FenoldopamHydralazine may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Hydralazine.Approved
FentiazacFentiazac may decrease the antihypertensive activities of Hydralazine.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Hydralazine.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Hydralazine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydralazine.Approved, Investigational
FloctafenineFloctafenine may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Hydralazine.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Hydralazine.Experimental
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Hydralazine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Hydralazine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hydralazine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Hydralazine.Approved, Vet Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Hydralazine.Experimental
GuanabenzHydralazine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelHydralazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineHydralazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Hydralazine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hydralazine.Approved, Investigational
GuanoclorHydralazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHydralazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHydralazine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hydralazine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Hydralazine.Experimental
HexamethoniumHydralazine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Hydralazine.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Hydralazine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydralazine.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Hydralazine.Approved, Vet Approved
HydroflumethiazideHydralazine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Hydralazine.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Hydralazine.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Hydralazine.Approved
IloprostIloprost may increase the hypotensive activities of Hydralazine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Hydralazine.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Hydralazine.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Hydralazine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydralazine.Approved
IndenololHydralazine may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Hydralazine.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Hydralazine.Withdrawn
IndoraminHydralazine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Hydralazine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hydralazine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Hydralazine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydralazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Hydralazine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Hydralazine.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Hydralazine.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Hydralazine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Hydralazine.Experimental
KetanserinHydralazine may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Hydralazine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydralazine.Approved
LacidipineHydralazine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostHydralazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
LercanidipineHydralazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Hydralazine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Hydralazine.Approved, Investigational
LevodopaHydralazine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Hydralazine.Approved, Investigational
LinsidomineHydralazine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Hydralazine.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Hydralazine.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Hydralazine.Approved, Investigational
LofexidineHydralazine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Hydralazine.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Hydralazine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Hydralazine.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Hydralazine.Illicit, Investigational, Withdrawn
MacitentanHydralazine may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Hydralazine.Approved
ManidipineHydralazine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Hydralazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydralazine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Hydralazine.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Hydralazine.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Hydralazine.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Hydralazine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Hydralazine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Hydralazine.Approved
MethoserpidineHydralazine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Hydralazine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hydralazine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydralazine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Hydralazine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Hydralazine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Hydralazine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydralazine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydralazine.Approved, Investigational
MetyrosineHydralazine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Hydralazine.Experimental
MibefradilHydralazine may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Hydralazine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Hydralazine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Hydralazine.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Hydralazine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hydralazine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Hydralazine.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Hydralazine.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Hydralazine.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydralazine.Approved, Investigational
MoxonidineHydralazine may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineHydralazine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Hydralazine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Hydralazine.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Hydralazine.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Hydralazine.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Hydralazine.Approved
NaftopidilHydralazine may increase the hypotensive activities of Naftopidil.Investigational
NaproxenNaproxen may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nebivolol.Approved, Investigational
NepafenacNepafenac may decrease the antihypertensive activities of Hydralazine.Approved
NesiritideThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Hydralazine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Hydralazine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Hydralazine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Hydralazine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Hydralazine.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Hydralazine.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Hydralazine.Approved
NiguldipineHydralazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineHydralazine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Hydralazine.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Hydralazine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Hydralazine.Approved
NitrendipineHydralazine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Hydralazine.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Hydralazine.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Hydralazine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Hydralazine.Approved
ObinutuzumabHydralazine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hydralazine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Hydralazine.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Hydralazine.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Hydralazine.Approved
OmapatrilatHydralazine may increase the hypotensive activities of Omapatrilat.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Hydralazine.Vet Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Hydralazine.Approved
OxprenololHydralazine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hydralazine.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Hydralazine.Approved
PargylinePargyline may increase the hypotensive activities of Hydralazine.Approved
ParthenolideParthenolide may decrease the antihypertensive activities of Hydralazine.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Hydralazine is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
PentoliniumHydralazine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydralazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Hydralazine.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Hydralazine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Hydralazine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Hydralazine.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Hydralazine.Approved
PhenoxybenzamineHydralazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydralazine.Withdrawn
PhentolamineHydralazine may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PinacidilHydralazine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Hydralazine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydralazine.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Hydralazine.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Hydralazine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Hydralazine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydralazine.Withdrawn
PolythiazideHydralazine may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Hydralazine.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Hydralazine.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Hydralazine.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Hydralazine.Approved
PrimidonePrimidone may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Hydralazine.Experimental
PropacetamolPropacetamol may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Hydralazine.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Hydralazine.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Hydralazine.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Hydralazine.Experimental
PTC299PTC299 may decrease the antihypertensive activities of Hydralazine.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Hydralazine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Hydralazine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Hydralazine.Approved
RasagilineRasagiline may increase the hypotensive activities of Hydralazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydralazine.Approved
RemikirenHydralazine may increase the hypotensive activities of Remikiren.Approved
RescinnamineHydralazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydralazine.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Hydralazine.Approved, Experimental, Investigational
RilmenidineHydralazine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Hydralazine is combined with Riociguat.Approved
RisperidoneHydralazine may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabHydralazine may increase the hypotensive activities of Rituximab.Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Hydralazine.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Hydralazine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydralazine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Hydralazine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Hydralazine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Hydralazine.Approved
SafrazineSafrazine may increase the hypotensive activities of Hydralazine.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Hydralazine.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Hydralazine.Approved
SaprisartanHydralazine may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Hydralazine.Approved, Investigational, Vet Approved
SelexipagHydralazine may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Hydralazine.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Hydralazine.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Hydralazine.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hydralazine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Hydralazine.Approved
SitaxentanHydralazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Hydralazine.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.Approved
SpiraprilHydralazine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Hydralazine.Approved
SRT501SRT501 may decrease the antihypertensive activities of Hydralazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Hydralazine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydralazine.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Hydralazine.Approved
SulindacSulindac may decrease the antihypertensive activities of Hydralazine.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Hydralazine.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Hydralazine.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
TalinololHydralazine may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydralazine.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Hydralazine.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Hydralazine.Approved, Investigational
TemocaprilHydralazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Hydralazine.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Hydralazine.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Hydralazine.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Hydralazine.Experimental
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Hydralazine.Approved
TerlipressinHydralazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineHydralazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydralazine.Approved, Investigational, Withdrawn
TheodrenalineHydralazine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Hydralazine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hydralazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Hydralazine.Approved
TiboloneHydralazine may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenHydralazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Hydralazine.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Hydralazine.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Hydralazine.Approved
TolazolineHydralazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Hydralazine.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Hydralazine.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Hydralazine.Approved
TolonidineHydralazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Hydralazine.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Hydralazine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Hydralazine.Approved
TranilastTranilast may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydralazine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydralazine.Approved
TravoprostHydralazine may increase the hypotensive activities of Travoprost.Approved
TreprostinilHydralazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Hydralazine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Hydralazine.Experimental
TrichlormethiazideHydralazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinHydralazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Hydralazine.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Hydralazine.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Hydralazine.Approved, Experimental
UdenafilUdenafil may increase the antihypertensive activities of Hydralazine.Approved, Investigational
UnoprostoneHydralazine may increase the hypotensive activities of Unoprostone.Approved
UrapidilHydralazine may increase the hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Hydralazine.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Hydralazine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hydralazine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.Approved
VincamineHydralazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineHydralazine may increase the hypotensive activities of Vinpocetine.Investigational
XipamideHydralazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineHydralazine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hydralazine.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Hydralazine.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Hydralazine.Approved, Investigational, Withdrawn
ZofenoprilHydralazine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Hydralazine.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,484,029.

General References
  1. Kandler MR, Mah GT, Tejani AM, Stabler SN: Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004934. doi: 10.1002/14651858.CD004934.pub3. [PubMed:20687078]
External Links
Human Metabolome Database
HMDB15400
KEGG Drug
D08044
KEGG Compound
C07040
PubChem Compound
3637
PubChem Substance
46507533
ChemSpider
3511
BindingDB
81461
ChEBI
5775
ChEMBL
CHEMBL276832
Therapeutic Targets Database
DAP000728
PharmGKB
PA449894
HET
HLZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Hydralazine
ATC Codes
C02DB02 — HydralazineC02LG02 — Hydralazine and diuretics
AHFS Codes
  • 24:08.20 — Direct Vasodilators
PDB Entries
3ltw
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHeart Failure, Unspecified1
1CompletedTreatmentHypertensive1
1CompletedTreatmentLung Cancers1
1, 2WithdrawnHealth Services ResearchCancer, Breast1
1, 2WithdrawnHealth Services ResearchRectal Carcinoma1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2CompletedTreatmentCervical Cancers1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentRefractory Solid Tumors1
2RecruitingTreatmentIntracerebral Hemorrhage1
2TerminatedTreatmentLocally Advanced Breast Cancer (LABC)1
2, 3CompletedTreatmentCardiac Failure / Congestive Heart Failure (CHF) / Heart Failure, Unspecified1
2, 3Unknown StatusTreatmentHydralazine Adverse Reaction / Pre-eclampsia Superimposed Pre-existing Hypertension / Pregnancy associated hypertension / Prophylaxis of preeclampsia1
3Active Not RecruitingTreatmentAcute Heart Failure (AHF) / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedTreatmentPregnancy associated hypertension1
3Not Yet RecruitingTreatmentCervical Cancers1
3Unknown StatusTreatmentCancer, Ovarian1
3Unknown StatusTreatmentCardio-Renal Syndrome1
3Unknown StatusTreatmentRecurrent, IV-B Cervical cancer1
4CompletedTreatmentCongestive Heart Failure (CHF)1
4CompletedTreatmentHypertensive1
4CompletedTreatmentStage II Hypertension1
4RecruitingPreventionChronic Hemodialysis (ESRD)1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedBasic ScienceHigh Blood Pressure1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableRecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableTerminatedTreatmentTreatment Induced Hypertension1
Not AvailableWithdrawnTreatmentHypertensive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous20 mg
Tablet, film coatedOral
InjectionIntramuscular; Intravenous20 mg/mL
Injection, solutionIntramuscular; Intravascular20 mg/mL
Injection, solutionIntramuscular; Intravenous20 mg/mL
TabletOral10 mg/1
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral
Prices
Unit descriptionCostUnit
Hydralazine 20 mg/ml vial18.0USD ml
Hydralazine 100 mg tablet1.65USD tablet
Hydralazine-HCTZ 50-50 mg capsule1.2USD capsule
HydrALAZINE HCl 100 mg tablet1.05USD tablet
Hydralazine-HCTZ 25-25 mg capsule0.81USD capsule
Hydralazine-HCTZ 100-50 mg capsule0.75USD capsule
HydrALAZINE HCl 50 mg tablet0.67USD tablet
Apresoline 50 mg tablet0.65USD tablet
HydrALAZINE HCl 25 mg tablet0.53USD tablet
HydrALAZINE HCl 10 mg tablet0.47USD tablet
Hydralazine 50 mg tablet0.44USD tablet
Hydralazine 25 mg tablet0.35USD tablet
Apo-Hydralazine 50 mg Tablet0.29USD tablet
Novo-Hylazin 50 mg Tablet0.29USD tablet
Apo-Hydralazine 25 mg Tablet0.24USD tablet
Hydralazine 10 mg tablet0.22USD tablet
Apo-Hydralazine 10 mg Tablet0.11USD tablet
Novo-Hylazin 10 mg Tablet0.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6465463No2000-09-082020-09-08Us
US6784177No2000-09-082020-09-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)172-173 °CU.S. Patent 2,484,029.
logP1.00SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility2.61 mg/mLALOGPS
logP0.66ALOGPS
logP0.75ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)17.69ChemAxon
pKa (Strongest Basic)6.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.83 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity50.23 m3·mol-1ChemAxon
Polarizability16.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9854
Blood Brain Barrier+0.9487
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.686
P-glycoprotein inhibitor INon-inhibitor0.9478
P-glycoprotein inhibitor IINon-inhibitor0.9826
Renal organic cation transporterNon-inhibitor0.8279
CYP450 2C9 substrateNon-substrate0.8971
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7467
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5294
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7719
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.2187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9253
hERG inhibition (predictor II)Non-inhibitor0.8589
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalazines. These are compounds containing a phthalazine moiety, which consists of a benzene ring fused to a pyridazine, forming a 2,3-benzodiazine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Phthalazines
Alternative Parents
Pyridazines and derivatives / Imidolactams / Benzenoids / Heteroaromatic compounds / Amidrazones / Hydrazones / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phthalazine / Imidolactam / Benzenoid / Pyridazine / Heteroaromatic compound / Carboxylic acid amidrazone / Azacycle / Hydrazone / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
hydrazines, phthalazines, azaarene, ortho-fused heteroarene (CHEBI:5775)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tryptamine:oxygen oxidoreductase (deaminating) activity
Specific Function
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-in...
Gene Name
AOC3
Uniprot ID
Q16853
Uniprot Name
Membrane primary amine oxidase
Molecular Weight
84621.27 Da
References
  1. Claud P, Padovani P, Guichard JP, Artur Y, Laine R: Involvement of semicarbazide-sensitive amine oxidase in tresperimus metabolism in human and in rat. Drug Metab Dispos. 2001 May;29(5):735-41. [PubMed:11302941]
  2. Vidrio H, Medina M, Gonzalez-Romo P, Lorenzana-Jimenez M, Diaz-Arista P, Baeza A: Semicarbazide-sensitive amine oxidase substrates potentiate hydralazine hypotension: possible role of hydrogen peroxide. J Pharmacol Exp Ther. 2003 Nov;307(2):497-504. Epub 2003 Sep 11. [PubMed:12970383]
  3. Vidrio H: Semicarbazide-sensitive amine oxidase: role in the vasculature and vasodilation after in situ inhibition. Auton Autacoid Pharmacol. 2003 Oct-Dec;23(5-6):275-83. [PubMed:15255812]
  4. Vidrio H, Medina M: 2-bromoethylamine, a suicide inhibitor of semicarbazide-sensitive amine oxidase, increases hydralazine hypotension in rats. J Cardiovasc Pharmacol. 2005 Sep;46(3):316-24. [PubMed:16116337]
  5. Vidrio H, Medina M: Hypotensive effect of hydroxylamine, an endogenous nitric oxide donor and SSAO inhibitor. J Neural Transm (Vienna). 2007;114(6):863-5. Epub 2007 Mar 26. [PubMed:17385063]
  6. Gronvall JL, Garpenstrand H, Oreland L, Ekblom J: An autoradiographic method of visualising semicarbazide-sensitive amine oxidase activity in mouse tissue sections. Neurobiology (Bp). 2000;8(2):167-77. [PubMed:11061213]
  7. Gronvall JL, Garpenstrand H, Oreland L, Ekblom J: Autoradiographic imaging of formaldehyde adducts in mice: possible relevance for vascular damage in diabetes. Life Sci. 1998;63(9):759-68. [PubMed:9740313]
  8. Lizcano JM, Fernandez de Arriba A, Tipton KF, Unzeta M: Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996 Jul 26;52(2):187-95. [PubMed:8694842]
  9. Lyles GA, McDougall SA: The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities. J Pharm Pharmacol. 1989 Feb;41(2):97-100. [PubMed:2568436]
  10. Barrand MA, Callingham BA: The interaction of hydralazine with a semicarbazide-sensitive amine oxidase in brown adipose tissue of the rat. Its use as a radioactive ligand for the enzyme. Biochem J. 1985 Dec 1;232(2):415-23. [PubMed:4091799]
  11. Barrand MA, Fox SA: Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline-resistant) activity at the fat cell membrane. J Pharm Pharmacol. 1984 Oct;36(10):652-8. [PubMed:6150080]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Procollagen-proline 4-dioxygenase activity
Specific Function
Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins.
Gene Name
P4HA1
Uniprot ID
P13674
Uniprot Name
Prolyl 4-hydroxylase subunit alpha-1
Molecular Weight
61048.775 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Knowles HJ, Tian YM, Mole DR, Harris AL: Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res. 2004 Jul 23;95(2):162-9. Epub 2004 Jun 10. [PubMed:15192023]
  3. Murad S, Tajima S, Pinnell SR: A paradoxical effect of hydralazine on prolyl and lysyl hydroxylase activities in cultured human skin fibroblasts. Arch Biochem Biophys. 1985 Sep;241(2):356-63. [PubMed:2994564]
  4. Chen KH, Paz MA, Gallop PM: Collagen prolyl hydroxylation in WI-38 fibroblast cultures: action of hydralazine. In Vitro. 1977 Jan;13(1):49-54. [PubMed:856725]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Zhao XJ, Ishizaki T: Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11. [PubMed:9384469]

Drug created on May 16, 2007 14:38 / Updated on November 13, 2017 21:49